TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11360607

Group type: COMPARATOR
Intervention: 25 mg mifepristone
Number of subjects: 2387

Group type: COMPARATOR
Intervention: 25 mg mifepristone plus 7.5 mg anordrin
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone plus 5 mg anordrin
Number of subjects: 2387

Group type: COMPARATOR
Intervention: 10 mg mifepristone
Number of subjects: 2387
Study: 7472907

Group type: EXPERIMENTAL
Intervention: LBWI formula with LCP (n = 9)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: LBWI formula without LCP (n = 10)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Mother's milk fortified with protein and minerals (n = 8)
Number of subjects: 27
Study: 2278323

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg, continuous infusion, with nitrous oxide in oxygen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg, continuous infusion, with nitrous oxide in oxygen (600 ng/litre)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg, continuous infusion, with oxygen in air (600 ng/litre)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in combination with midazolam
Number of subjects: 30
Study: 7374550

Group type: EXPERIMENTAL
Intervention: Identical diffuse immunoblastic lymphoma
Number of subjects: 2
Study: 28987525

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (320/1,600 mg twice daily for 7 days)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057
Study: 27465353

Group type: EXPERIMENTAL
Intervention: IC adrenaline ± verapamil through a well-cannulated guiding catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local injection of adrenaline ± verapamil in the distal coronary bed through a perfusion balloon or selective microcatheter
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24105084

Group type: EXPERIMENTAL
Intervention: Embrace device treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 12
Study: 22447494

Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels in NP patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no nasal polyposis)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison of serum IL-16 levels
Number of subjects: 27
Study: 20470337

Group type: EXPERIMENTAL
Intervention: Propofol LCT premixed with lignocaine (0.1%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT premixed with lignocaine (0.1%)
Number of subjects: 80
Study: 18188105

Group type: EXPERIMENTAL
Intervention: Intravenous ethanol infusion (EtOH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scheduled-dose diazepam (BENZO)
Number of subjects: 50
Study: 15919488

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 557
Study: 12699021

Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Parent and teacher training (PT + TT)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Experimental conditions (PT and PT + TT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Waiting list control (C)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Teacher training (TT)
Number of subjects: 208
Study: 11086638

Group type: EXPERIMENTAL
Intervention: Heparin infusion for at least 5 days
Number of subjects: 1221

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1221
Study: 8781002

Group type: EXPERIMENTAL
Intervention: Audio feedback through the use of audiotaped role plays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role plays with peer feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional didactic lecture mode
Number of subjects: 0
Study: 1468246

Group type: EXPERIMENTAL
Intervention: Oral sulodexide (2 capsules of 250 lipoproteinolipase releasing units twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (2 identical capsules twice daily)
Number of subjects: 36
Study: 6475654

Group type: EXPERIMENTAL
Intervention: Frusemide with potassium supplements (48 mmol/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Frusemide alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretic
Number of subjects: 9
Study: 3097108

Group type: EXPERIMENTAL
Intervention: Double-blind food challenge with lyophilized food in capsules or food mixed in broth
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (300 mg 30 minutes before food challenge)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 300
Study: 31023398

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (three commonly prescribed antidepressants)
Number of subjects: 1008
Study: 30392345

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) combined with parenteral nutrition (PN)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: EEN+ PN in centrally located HCC (cl-HCC)
Number of subjects: 379

Group type: COMPARATOR
Intervention: TPN in centrally located HCC (cl-HCC)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: EEN+ PN in non-centrally located HCC (ncl-HCC)
Number of subjects: 379

Group type: COMPARATOR
Intervention: TPN in non-centrally located HCC (ncl-HCC)
Number of subjects: 379
Study: 26337132

Group type: EXPERIMENTAL
Intervention: Categories of eGFR (estimated glomerular filtration rates)
Number of subjects: 19411
Study: 23382580

Group type: EXPERIMENTAL
Intervention: High-intensity computerized working memory training in school setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22425474

Group type: EXPERIMENTAL
Intervention: Inpatient treatment based on cognitive behavior therapy for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (10 females)
Number of subjects: 16
Study: 20379679

Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with ZO‐eugenol (ZOE)‐based cement (Group IV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: RelyX Unicem cement with ZO‐eugenol (ZOE)‐based cement (Group VIII)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with Ca(OH)2‐based cement (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with zinc oxide (ZO)‐based cement (Group III)
Number of subjects: 40

Group type: COMPARATOR
Intervention: RelyX Unicem cement with Ca(OH)2‐based cement (Group VI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: RelyX Unicem cement with zinc oxide (ZO)‐based cement (Group VII)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with no temporary cementation (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: RelyX Unicem cement with no temporary cementation (Group V)
Number of subjects: 40
Study: 18355634

Group type: EXPERIMENTAL
Intervention: Strong-alpha 3 sub-group (high band power)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Weak-alpha 3 sub-group (low band power)
Number of subjects: 10
Study: 15778428

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/week subcutaneous efalizumab for 12 weeks
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: 2 mg/kg/week subcutaneous efalizumab for 12 weeks
Number of subjects: 1088
Study: 12686232

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 92

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 92
Study: 10898434

Group type: EXPERIMENTAL
Intervention: Oxygen Uptake Efficiency Slope (OUES) calculated from the first 75% of the exercise test
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: OUES
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: OUES in congestive heart failure patients
Number of subjects: 1010
Study: 8858790

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 0
Study: 1332463

Group type: EXPERIMENTAL
Intervention: Guava fruit intake (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 120
Study: 3968617

Group type: EXPERIMENTAL
Intervention: SMA Gold Cap (Group A)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Supplementary calcium to 21 mmol/L (Group B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Further calcium supplementation to 31.2 mmol/L (Group C)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Milk with calcium content 31.2 mmol/L and phosphorus supplementation to 15.7 mmol/L (Group D)
Number of subjects: 74
Study: 29489730

Group type: EXPERIMENTAL
Intervention: Bounce technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pause technique
Number of subjects: 20
Study: 29909873

Group type: EXPERIMENTAL
Intervention: Navigation program (personalized support by social workers)
Number of subjects: 16250

Group type: EXPERIMENTAL
Intervention: Navigation program
Number of subjects: 16250

Group type: COMPARATOR
Intervention: Usual screening
Number of subjects: 16250
Study: 25416755

Group type: EXPERIMENTAL
Intervention: 4-week NRT supply
Number of subjects: 1495

Group type: COMPARATOR
Intervention: 8-week NRT supply (split-shipment protocol)
Number of subjects: 1495
Study: 24852701

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg 1 hour before sexual intercourse
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nasal CPAP during night time sleep
Number of subjects: 82
Study: 21380565

Group type: EXPERIMENTAL
Intervention: Prophylactic normothermia group with target core temperature 36.5°C using endovascular cooling
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional temperature management using antipyretic medication and surface cooling (active control group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups (endovascular and conventional)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Endovascular group with NSAIDs
Number of subjects: 63
Study: 20212256

Group type: EXPERIMENTAL
Intervention: Recurrence Score (RS) in N0 patients
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: Recurrence Score (RS) in N+ patients
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: Recurrence Score (RS) in both N0 and N+ patients
Number of subjects: 1231
Study: 17545052

Group type: EXPERIMENTAL
Intervention: Huafenqinutang combined with vardenafil for 8 weeks (vardenafil added from week 5)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group treated with Huafenqinutang for 8 weeks
Number of subjects: 138
Study: 16353044

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day, n=20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, n=18)
Number of subjects: 38
Study: 12168367

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 117

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 117

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 117
Study: 14564602

Group type: EXPERIMENTAL
Intervention: 1.2% isoflurane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.7% sevoflurane
Number of subjects: 12
Study: 8941005

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) treatment at doses of 600, 800 or 1200 mg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) treatment
Number of subjects: 21
Study: 1338084

Group type: EXPERIMENTAL
Intervention: Metoprolol (controlled release)
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Amiloride (diuretic)
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Supplementary treatment (beta-blocker to diuretic, or vice versa)
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: All active treatment regimens
Number of subjects: 1627
Study: 6372360

Group type: EXPERIMENTAL
Intervention: 2 mg PGE2 pessary
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 pessary
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5 mg PGE2 pessary
Number of subjects: 180
Study: 31044234

Group type: EXPERIMENTAL
Intervention: Unintended pregnancy
Number of subjects: 400
Study: 30356308

Group type: EXPERIMENTAL
Intervention: Dehydration (2% bodyweight deficit) during high heat stress (HYPER)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Euhydration during high heat stress (HYPER)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Moderate heat stress (MOD)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Euhydration (full fluid replacement)
Number of subjects: 139
Study: 28211106

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 30
Study: 25786769

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg q.d.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Esomeprazole 10 mg q.d.
Number of subjects: 11
Study: 23174486

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy defibrillator (CRT-D)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: CRT-D in LBBB patients
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: CRT-D in non-LBBB patients
Number of subjects: 1209
Study: 21999631

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 200 mg twice daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r) 300/100 mg once daily
Number of subjects: 152
Study: 18456465

Group type: EXPERIMENTAL
Intervention: Azithromycin extended release (AZ‐ER) 2g single dose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Azithromycin immediate release (AZ‐IR) 500mg daily for 3 days
Number of subjects: 9
Study: 16801649

Group type: EXPERIMENTAL
Intervention: Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy in DLB patients
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Delayed H/M ratio in DLB patients
Number of subjects: 89

Group type: COMPARATOR
Intervention: Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy in AD patients
Number of subjects: 89

Group type: COMPARATOR
Intervention: Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy in DLB/P+ and DLB/P- patients
Number of subjects: 89
Study: 14528776

Group type: EXPERIMENTAL
Intervention: Phosphoric Acid (PA) etching with Prime & Bond NT (PBNT) on permanent dentin (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phosphoric Acid (PA) etching with Prime & Bond NT (PBNT) on primary dentin (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-Rinse Conditioner (NRC) with Prime & Bond NT (PBNT) on permanent dentin (Group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-Rinse Conditioner (NRC) with Prime & Bond NT (PBNT) on primary dentin (Group IV)
Number of subjects: 40
Study: 11205362

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of viral infection episodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Number of subjects: 0
Study: 9488243

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (n = 11)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lisinopril (n = 13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS and Lisinopril
Number of subjects: 25
Study: 8453797

Group type: EXPERIMENTAL
Intervention: Intra-articular steroids
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bed rest only
Number of subjects: 25
Study: 2426829

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-pulsatile perfusion
Number of subjects: 51
Study: 30272096

Group type: EXPERIMENTAL
Intervention: HBP Group (physical training using the HBP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise Group (training without the use of the orthosis)
Number of subjects: 20
Study: 26321012

Group type: EXPERIMENTAL
Intervention: DASH-Plus intervention (coach-directed dietary advice, assistance with online ordering and purchasing of high-potassium foods, $30/week)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (printed DASH diet brochure, debit account of equivalent value)
Number of subjects: 123
Study: 23742737

Group type: EXPERIMENTAL
Intervention: nabiximols (oral mucosal spray containing cannabinoids)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 23538392

Group type: EXPERIMENTAL
Intervention: Smartphone intervention with diaries and therapist feedback
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no smartphone intervention)
Number of subjects: 140
Study: 20723437

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial perfusion of batroxobin combined with TACE
Number of subjects: 40

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 40
Study: 18466670

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 289

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 289
Study: 16636857

Group type: EXPERIMENTAL
Intervention: Sublingual androstenediol (SL-DIOL) with exercise (EX)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sublingual androstenediol (SL-DIOL) without exercise (Rest)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sublingual androstenediol (SL-DIOL)
Number of subjects: 6
Study: 12897317

Group type: EXPERIMENTAL
Intervention: Clinician-facilitated intervention (6 to 11 sessions, including separate meetings with parents and children)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Lecture intervention (2 separate meetings in a group format without children present)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both interventions (Clinician-facilitated and Lecture)
Number of subjects: 121
Study: 10711585

Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 1192
Study: 9005501

Group type: EXPERIMENTAL
Intervention: IHB before incision using 0.25 ml/kg bupivacaine 0.5%
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IHB after incision using 0.25 ml/kg bupivacaine 0.5%
Number of subjects: 68

Group type: COMPARATOR
Intervention: IHB before incision with 0.25 ml/kg of serum
Number of subjects: 68

Group type: COMPARATOR
Intervention: IHB after incision with 0.25 ml/kg of serum
Number of subjects: 68
Study: 8151594

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms oral dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3167937

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (high nicotine content)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (low nicotine content)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nicotine gum chewing
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study: 29480182

Group type: EXPERIMENTAL
Intervention: Simultaneous memory training and aerobic exercise (SIM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sequential memory training after stationary cycling (SEQ)
Number of subjects: 55
Study: 28199799

Group type: EXPERIMENTAL
Intervention: 20 g protein hydrolysate
Number of subjects: 24

Group type: COMPARATOR
Intervention: iso-caloric carbohydrate
Number of subjects: 24

Group type: COMPARATOR
Intervention: low-calorific placebo
Number of subjects: 24
Study: 25785646

Group type: EXPERIMENTAL
Intervention: Child-Directed Interaction Training (CDIT)
Number of subjects: 30
Study: 23930444

Group type: EXPERIMENTAL
Intervention: Online support group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 21381272

Group type: EXPERIMENTAL
Intervention: Various treatment options
Number of subjects: 0
Study: 19373128

Group type: EXPERIMENTAL
Intervention: Optical coherence tomograms (OCT) with erroneous centerpoint thickness needing manual remeasurement (MR)
Number of subjects: 6741

Group type: EXPERIMENTAL
Intervention: Age-related macular degeneration (AMD)
Number of subjects: 6741

Group type: EXPERIMENTAL
Intervention: Retinal vein occlusion
Number of subjects: 6741

Group type: EXPERIMENTAL
Intervention: Diabetic macular edema
Number of subjects: 6741

Group type: EXPERIMENTAL
Intervention: Boundary line errors
Number of subjects: 6741

Group type: EXPERIMENTAL
Intervention: Decentration artifact
Number of subjects: 6741

Group type: EXPERIMENTAL
Intervention: Median absolute difference between machine and manually measured centerpoint thickness
Number of subjects: 6741
Study: 17545057

Group type: EXPERIMENTAL
Intervention: Removable lingual arch plus auxiliary spring
Number of subjects: 17

Group type: COMPARATOR
Intervention: Quad-helix
Number of subjects: 17
Study: 15065730

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Routine mailing only
Number of subjects: 1061
Study: 11488742

Group type: EXPERIMENTAL
Intervention: 2% mercurochrome applied for 48 hours before surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional local scrub with soap/water
Number of subjects: 44
Study: 9503217

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7567201

Group type: EXPERIMENTAL
Intervention: Direct extubation from IMV (D.EXT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Preextubation endotracheal CPAP (ET‐CPAP) for 12‐24 hr
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Postextubation nasopharyngeal CPAP (NP‐CPAP) for 12‐24 hr
Number of subjects: 87

Group type: COMPARATOR
Intervention: Preextubation endotracheal CPAP (ET‐CPAP)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Postextubation nasopharyngeal CPAP (NP‐CPAP)
Number of subjects: 87
Study: 2356812

Group type: EXPERIMENTAL
Intervention: Regular coffee (5 cups per day for 6 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Decaffeinated coffee (5 cups per day for 6 weeks)
Number of subjects: 45